Hemagglutinin-Specific Antibody-Dependent Cell-Mediated Cytotoxicity–Mediating Antibody Response Induced by Either MF59- or AS03-Adjuvanted A(H7N9) Candidate Vaccine Virus
| Adjuvant . | Serum Pairsa . | rH7 Antigen . | Pre-GMT (95% CI) . | Post-GMT (95% CI) . | Seroconversion, No. (%)b . |
|---|---|---|---|---|---|
| MF59 | n = 30 | SH2 | 36.5 (27.18–48.94) | 508.0 (365.8–705.4) | 28/30 (93.3) |
| HK61 | 35.6 (25.53–49.74) | 468.5 (341.0–643.7) | 28/30 (93.3) | ||
| HK125 | 34.8 (26.23–46.24) | 359.2 (258.7–498.8) | 28/30 (93.3) | ||
| GD17S | 42.9 (32.04–57.36) | 485.1 (365.5–643.8) | 26/30 (86.7) | ||
| AS03 | n = 30 | SH2 | 33.2 (26.8–41.2) | 678.1 (530.6–866.5) | 30/30 (100) |
| HK61 | 31.7 (26.1–38.6) | 611.1 (474.2–787.6) | 30/30 (100) | ||
| HK125 | 38.2 (30.8–47.3) | 412.6 (333.8–510.1) | 30/30 (100) | ||
| GD17S | 42.4 (31.9–56.3) | 611.1 (497.4–750.9) | 29/30 (96.7) |
| Adjuvant . | Serum Pairsa . | rH7 Antigen . | Pre-GMT (95% CI) . | Post-GMT (95% CI) . | Seroconversion, No. (%)b . |
|---|---|---|---|---|---|
| MF59 | n = 30 | SH2 | 36.5 (27.18–48.94) | 508.0 (365.8–705.4) | 28/30 (93.3) |
| HK61 | 35.6 (25.53–49.74) | 468.5 (341.0–643.7) | 28/30 (93.3) | ||
| HK125 | 34.8 (26.23–46.24) | 359.2 (258.7–498.8) | 28/30 (93.3) | ||
| GD17S | 42.9 (32.04–57.36) | 485.1 (365.5–643.8) | 26/30 (86.7) | ||
| AS03 | n = 30 | SH2 | 33.2 (26.8–41.2) | 678.1 (530.6–866.5) | 30/30 (100) |
| HK61 | 31.7 (26.1–38.6) | 611.1 (474.2–787.6) | 30/30 (100) | ||
| HK125 | 38.2 (30.8–47.3) | 412.6 (333.8–510.1) | 30/30 (100) | ||
| GD17S | 42.4 (31.9–56.3) | 611.1 (497.4–750.9) | 29/30 (96.7) |
Abbreviations: CI, confidence interval; GMT, geometric mean titer.
pre- day 0 of the vaccination. post- day 42–52 after the second dose of the vaccination.
aTwo panels of paired serum samples were collected from individuals who were immunized with either MF59- or AS03-adjuvanted inactivated A(H7N9) candidate vaccine virus manufactured based on SH2 virus. HA-specific antibody-dependent cell-mediated cytotoxicity (ADCC)–mediating antibodies in the sera were determined by an ADCC natural killer cell activation assay using full-length recombinant H7 antigens as indicated.
bSeroconversion refers to a ≥4-fold titer rise of ADCC antibodies after the second dose of the vaccination.
Hemagglutinin-Specific Antibody-Dependent Cell-Mediated Cytotoxicity–Mediating Antibody Response Induced by Either MF59- or AS03-Adjuvanted A(H7N9) Candidate Vaccine Virus
| Adjuvant . | Serum Pairsa . | rH7 Antigen . | Pre-GMT (95% CI) . | Post-GMT (95% CI) . | Seroconversion, No. (%)b . |
|---|---|---|---|---|---|
| MF59 | n = 30 | SH2 | 36.5 (27.18–48.94) | 508.0 (365.8–705.4) | 28/30 (93.3) |
| HK61 | 35.6 (25.53–49.74) | 468.5 (341.0–643.7) | 28/30 (93.3) | ||
| HK125 | 34.8 (26.23–46.24) | 359.2 (258.7–498.8) | 28/30 (93.3) | ||
| GD17S | 42.9 (32.04–57.36) | 485.1 (365.5–643.8) | 26/30 (86.7) | ||
| AS03 | n = 30 | SH2 | 33.2 (26.8–41.2) | 678.1 (530.6–866.5) | 30/30 (100) |
| HK61 | 31.7 (26.1–38.6) | 611.1 (474.2–787.6) | 30/30 (100) | ||
| HK125 | 38.2 (30.8–47.3) | 412.6 (333.8–510.1) | 30/30 (100) | ||
| GD17S | 42.4 (31.9–56.3) | 611.1 (497.4–750.9) | 29/30 (96.7) |
| Adjuvant . | Serum Pairsa . | rH7 Antigen . | Pre-GMT (95% CI) . | Post-GMT (95% CI) . | Seroconversion, No. (%)b . |
|---|---|---|---|---|---|
| MF59 | n = 30 | SH2 | 36.5 (27.18–48.94) | 508.0 (365.8–705.4) | 28/30 (93.3) |
| HK61 | 35.6 (25.53–49.74) | 468.5 (341.0–643.7) | 28/30 (93.3) | ||
| HK125 | 34.8 (26.23–46.24) | 359.2 (258.7–498.8) | 28/30 (93.3) | ||
| GD17S | 42.9 (32.04–57.36) | 485.1 (365.5–643.8) | 26/30 (86.7) | ||
| AS03 | n = 30 | SH2 | 33.2 (26.8–41.2) | 678.1 (530.6–866.5) | 30/30 (100) |
| HK61 | 31.7 (26.1–38.6) | 611.1 (474.2–787.6) | 30/30 (100) | ||
| HK125 | 38.2 (30.8–47.3) | 412.6 (333.8–510.1) | 30/30 (100) | ||
| GD17S | 42.4 (31.9–56.3) | 611.1 (497.4–750.9) | 29/30 (96.7) |
Abbreviations: CI, confidence interval; GMT, geometric mean titer.
pre- day 0 of the vaccination. post- day 42–52 after the second dose of the vaccination.
aTwo panels of paired serum samples were collected from individuals who were immunized with either MF59- or AS03-adjuvanted inactivated A(H7N9) candidate vaccine virus manufactured based on SH2 virus. HA-specific antibody-dependent cell-mediated cytotoxicity (ADCC)–mediating antibodies in the sera were determined by an ADCC natural killer cell activation assay using full-length recombinant H7 antigens as indicated.
bSeroconversion refers to a ≥4-fold titer rise of ADCC antibodies after the second dose of the vaccination.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
